Lantern Pharma Inc. has landed a nearly $1 million investment from Dallas-based Green Park & Golf Ventures and other investors.
The Dallas startup, which focuses on novel cancer treatments, is a graduate of the 2014 Health Wildcatters class.
"The investment from GPG helps us bring the next generation of cancer therapies to patients who need them," Lantern Pharma CEO Dr. Arun Asaithambi said.
Lantern Pharma combines a drug platform with diagnostics and data analytics in cancer medicine to identify and treat patients. The company is initially focused on prostate and ovarian cancers. It is led by Asaithambi, a biotechnology scientist and entrepreneur who formerly was the cofounding CEO of Signal Therapeutics.
Green Park & Golf Ventures, an angel investment firm which typically funds Texas-based health care startups, is a co-founder and investor of Health Wildcatters and previously invested $400,000 to Richardson startup Cariloop.
Source : http://www.bizjournals.com/